Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: Land Shark who wrote (15299)	5/7/1998 7:51:00 AM
From: Logistics	Read Replies (1) \| Respond to of 34592

Penny Players: MTCH DD \| Next \| Respond \| Remove Navigation To: Logistics (61 ) From: B.MCVEE Wednesday, May 6 1998 9:38PM ET Reply # of 79 MTCH.... Could be interesting Overview Meditech Pharmaceuticals, Inc. EXECUTIVE SUMMARY Meditech Pharmaceuticals, Inc. (Meditech or the Company) is a publicly traded company, focusing in the areas of research, development, and marketing in the biomedical industry. Meditech's R & D efforts are concentrated in the area of anti-viral and anti-microbial drugs for ethical, over-the-counter, veterinary, and agricultural use. The Company was organized in 1983. Patents Five U.S. patents totalling 59 claims have been granted for anti-viral and anti-bacterial uses of its drug MTCH-24'. In addition, three Canadian patents were issued in 1988 and 1989 granting 18 anti-viral claims, and an Italian patent was granted in November 1988 on Viraplex for use as a Herpes simplex treatment. Other patents have been allowed in nine countries. Management Meditech's management, directors, and advisers have significant experience in biomedical research, product marketing, and consumer products distribution. Products Viraplex promises to prove useful in the treatment of orofacial and genital Herpes simplex. The drug is in Phase III clinical trials for safety and efficacy in humans. The genital Herpes portion of the trials has been completed, and preliminary analysis shows Viraplex to be safe and effective. MTCH-24 has been successfully tested in the laboratory against the Herpes simplex virus, cytomegalovirus, Epstein-Barr virus, rotavirus, and other enveloped viruses. It also has been shown effective in laboratory tests against gram-positive bacteria, including staphylococcus and streptococcus, and certain fungi, including Candida albicans. MTCH-24 has also demonstrated effectiveness in laboratory and field tests against Xanthomonas campestris, the organism which causes citrus canker, and against Aflatoxin, a major problem in stored corn and other grains. ------------------------------------------------------------------------ --------